Background
Treatment for glioblastoma (GBM) remains an unmet need in medicine. Novel therapies that address GBM complexity and heterogeneity in particular are warranted. To this end, we target four tumor-associated receptors at a time that span virtually all of the GBM microenvironment including bulk tumor cells, infiltrating tumor cells, neovasculature and tumor infiltrating cells with one pharmaceutical agent delivering a cytotoxic load.
Methods
We engineered multivalent ligand-based vector proteins termed QUAD with an ability to bind to four GBM-associated receptors: IL-13RA2, EphA2, EphA3, and EphB2. We conjugated QUAD with a modified bacterial toxin PE38QQR, and tested it in vitro and in vivo.
Results
The QUAD variants preserved functional characteristics of the respective ligands for the four receptors. The QUAD 3.0 variant conjugate was highly cytotoxic to GBM cells, but it was non-toxic in mice, and the conjugate exhibited strong anti-tumor effect in a dog with spontaneous GBM.
Conclusion
The QUAD addresses, to a large extent, the issues of intra- and inter-tumoral heterogeneity and, at the same time, it targets several pathophysiologically important tumor compartments in GBM through multiple receptors over-expressed in tumors allowing for what we call “molecular resection”. QUAD-based targeted agents warrant further pre- and clinical development.